AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 184 filers reported holding AERIE PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.44 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $13,000 | -31.6% | 365 | +15.9% | 0.01% | -28.6% |
| Q3 2018 | $19,000 | -9.5% | 315 | 0.0% | 0.01% | -12.5% |
| Q2 2018 | $21,000 | +75.0% | 315 | +37.6% | 0.01% | +60.0% |
| Q1 2018 | $12,000 | -14.3% | 229 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $14,000 | +55.6% | 229 | +18.7% | 0.01% | +25.0% |
| Q3 2017 | $9,000 | +50.0% | 193 | +59.5% | 0.00% | +100.0% |
| Q2 2017 | $6,000 | – | 121 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |